ANCA evolution and B-cell detection patterns throughout follow-up for patients with ≥1 relapses or none
| Parameter profile | Patients with | |
| ≥1 relapse(s) (n=22)* | No relapse (n=139) | |
| ANCA evolution (%) | ||
| Always negative | 7 (31.8) | 33 (23.7) |
| Negative at inclusion and became positive | 3 (13.6) | 14 (10.1) |
| Positive at inclusion and became negative | 2 (9.1) | 51 (36.7) |
| Positive at inclusion and titres rose | 1 (4.5) | 10 (7.2) |
| Positive at inclusion and remained stable | 9 (40.9) | 29 (20.9) |
| Circulating CD19+ B cell evolution (%) | ||
| Always negative | 11 (50) | 8 (5.8) |
| Detected at least once | 11 (50) | 131 (94.2) |
| ANCA and circulating CD19+ B cell evolutions (%) | ||
| ANCA-negative and no circulating B cells detected | 4 (18.2) | 5 (3.6) |
| Other | 18 (81.8) | 134 (96.4) |
Values are expressed as n (%).
*At the last visit, 23 patients had suffered 24 relapses; 2 relapses that occurred after month 28 were censored in the principal analysis. Thus, with 1 missing value and 1 patient who relapsed twice, we have 22 patients with ≥1 relapses.